


AMENDMENTS TO THE CLAIMS

Please amend the claims as follows:

Claims 1-58 (Canceled)

Claim 59. (New): A glycoconjugate having the structure:



wherein n and p are each independently an integer from 1-6;


m', n' and p' are independently integers between about 8 and 20;

j is an integer between 1 and about 8;

R is a nitrogen protecting group;


R_V, and R_B, R_C, and R_D, for each occurrence, are independently hydrogen, substituted or unsubstituted linear or branched lower alkyl or substituted or unsubstituted phenyl;

each occurrence of R_A is independently a carbohydrate domain having the structure:



wherein a, b, c, d, e, f, g, h, i, x, y and z are each independently 0, 1, 2 or 3, with the proviso that R_A, for each occurrence, is independently a carbohydrate comprised of furanose or pyranose moieties, whereby the sum of b and c is 1 or 2, the sum of d and f is 1 or 2, and the sum of g and i is 1 or 2, and with the proviso that x, y and z are not simultaneously 0; wherein R_0 is a hydrogen, linear or branched chain alkyl, acyl, arylalkyl or aryl group; wherein each occurrence

of R_1 , R_2 , R_3 , R_4 , R_5 , R_6 , R_7 , R_8 , and R_9 is independently hydrogen, OH, OR^i , NH_2 , $NHCO R^i$, F, CH_2OH , CH_2OR^i , a substituted or unsubstituted linear or branched chain alkyl, (mono-, di- or tri)hydroxyalkyl, (mono-, di- or tri)acyloxyalkyl, arylalkyl, or aryl group; wherein each occurrence of R^i is independently hydrogen, CHO, CO_2R^{ii} , a substituted or unsubstituted linear or branched chain alkyl, arylalkyl, or aryl group, or a saccharide moiety having the structure:




wherein Y and Z are independently NH or O; wherein k, l, r, s, t, u, v and w are each independently 0, 1 or 2, with the proviso that the v and w bracketed structures represent furanose or pyranose moieties and the sum of l and k is 1 or 2, and the sum of s and u is 1 or 2, and with the proviso that v and w are not simultaneously 0; wherein R'_0 is hydrogen, a linear or branched chain alkyl, acyl, arylalkyl or aryl group; wherein each occurrence of R_{10} , R_{11} , R_{12} , R_{13} , R_{14} and R_{15} is independently hydrogen, OH, OR^{iii} , NH_2 , $NHCO R^{iii}$, F, CH_2OH , CH_2OR^{iii} , or a substituted or unsubstituted linear or branched chain alkyl, (mono-, di- or tri)hydroxyalkyl, (mono- di- or tri-)acyloxyalkyl, arylalkyl or aryl group; wherein R_{16} is hydrogen, CO_2H , CO_2R^{ii} , $CONHR^{ii}$, a substituted or unsubstituted linear or branched chain alkyl or aryl group; wherein each occurrence of R^{iii} is independently hydrogen, CHO, CO_2R^{iv} , or a substituted or unsubstituted linear or branched chain alkyl, arylalkyl or aryl group; and wherein each occurrence of R^{ii} and R^{iv} is independently hydrogen, or a substituted or unsubstituted linear or branched chain alkyl, acyl, arylalkyl or aryl group.

Claim 60. (New): The glycoconjugate of claim 59, wherein R_V and R_B , for each occurrence, are independently methyl.


Claim 61. (New): The glycoconjugate of claim 59, wherein R_V and R_B , for each occurrence, are independently hydrogen.

Claim 62. (New): The glycoconjugate of claim 59, wherein n is 3; and each occurrence of R_B is independently hydrogen or methyl.

Claim 63. (New): The glycoconjugate of claim 59, wherein the p bracketed structure is a moiety having the structure:



Claim 64. (New): The glycoconjugate of claim 59, wherein n is 3; and the p bracketed structure is a moiety having the structure:



Claim 65. (New): The glycoconjugate of claim 59, wherein the carbohydrate domains are independently monosaccharides or disaccharides.

Claim 66. (New): The glycoconjugate of claim 59, wherein x and y are 0; wherein z is 1; and wherein R₃ is NHAc.

Claim 67. (New): The glycoconjugate of claim 59, wherein h is 0; wherein g and i are 1; wherein R₇ is OH; wherein R₀ is hydrogen; and wherein R₈ is hydroxymethyl.


Claim 68. (New): The glycoconjugate of claim 59, wherein m', n' and p' are each 14; and j is 3.

Claim 69. (New): The glycoconjugate of claim 59, wherein each amino acyl residue therein has an L-configuration.


Claim 70. (New): The glycoconjugate of claim 59, wherein R is Fmoc or Ac.

Claim 71. (New): The glycoconjugate of claim 59, wherein each occurrence of R_A is independently α - or β -linked to the peptide backbone.


Claim 72. (New): The glycoconjugate of claim 59, wherein each occurrence of R_A is independently a carbohydrate domain selected from the group consisting of TF, 2,6-STF, 3-Le^y, 6-Le^y, 2,3-ST, a carbohydrate having the structure:




a carbohydrate having the structure:



a carbohydrate having the structure:



wherein j' , k' and l' are each independently 0, 1 or 2; and a Le^y carbohydrate having the structure:



wherein j' and k' are each independently 0, 1 or 2.

Claim 73. (New): The glycoconjugate of claim 59, wherein each occurrence of R_A is independently Tn.

Claim 74. (New): The glycoconjugate of claim 59, wherein each occurrence of R_A is independently TF.

Claim 75. (New): The glycoconjugate of claim 59, wherein each occurrence of R_A is independently 2,6-STF.


Claim 76. (New): The glycoconjugate of claim 59, wherein each occurrence of R_A is independently 2,6-STn.

Claim 77. (New): The glycoconjugate of claim 59, wherein each occurrence of R_A is independently 3-Le^y or 6-Le^y.


Claim 78. (New): The glycoconjugate of claim 59, wherein each occurrence of R_A is independently 3,6-STn.

Claim 79. (New): The glycoconjugate of claim 59, wherein each occurrence of R_A is independently 2,3-ST.

Claim 80. (New): The glycoconjugate of claim 59, wherein each occurrence of R_A is independently a carbohydrate having the structure:




Claim 81. (New): The glycoconjugate of claim 59, wherein each occurrence of R_A is independently a carbohydrate having the structure:




wherein j' , k' and l' are each independently 0, 1 or 2.

Claim 82. (New): The glycoconjugate of claim 59, wherein each occurrence of R_A is independently a glycoporphine antigen having the structure:




Claim 83. (New): The glycoconjugate of claim 59, wherein each occurrence of R_A is independently a Le^y carbohydrate having the structure:




wherein j' and k' are each independently 0, 1 or 2.

Claim 84. (New): The glycoconjugate of claim 59, wherein n is 3; the p bracketed structure is a moiety having the structure:


Claim 86. (New): The glycoconjugate of claim 59, wherein n is 3; the p bracketed structure is a moiety having the structure:




and each occurrence of R_A is α -O-linked to the peptide backbone, wherein R_A , for each occurrence, is a Le^y pentasaccharide having the structure:



Claim 87. (New): The glycoconjugate of claim 59, wherein n is 3; the p bracketed structure is a moiety having the structure:



and each occurrence of R_A is β -O-linked to the peptide backbone, wherein R_A , for each occurrence, is a Le^y pentasaccharide having the structure:



Claim 88. (New): A pharmaceutical composition for treating cancer comprising a glycoconjugate of claim 1; and a pharmaceutically suitable carrier.

Claim 89. (New): The pharmaceutical composition of claim 88, wherein the glycoconjugate is present in an amount effective to elicit antibodies, wherein the antibodies are capable of specifically binding with human tumor cells.

Claim 90. (New): A method of treating cancer in a subject suffering therefrom comprising administering to the subject a therapeutically effective amount of a glycoconjugate of claim 1.

Claim 91. (New): A method of inducing antibodies in a subject, wherein the antibodies are capable of specifically binding with human tumor cells, which comprises administering to the subject an amount of a glycoconjugate of claim 1 effective to induce the antibodies.

Claim 92. (New): A method of preventing recurrence of epithelial cancer in a subject which comprises administering to a subject an amount of a glycoconjugate of claim 1 effective to induce antibodies.

Claim 93. (New): The method of claim 90, wherein the cancer is a solid tumor.

Claim 94. (New): The method of claim 90, wherein the cancer is an epithelial cancer.

Claim 95. (New): The method of claim 90, 91 or 92, wherein the method further comprises co-administering a pharmaceutically suitable carrier.

Claim 96. (New): The method of claim 90, 91 or 92, wherein the method further comprises co-administering an immunological adjuvant.

Claim 97. (New): The method of claim 96, wherein the adjuvant is bacteria or liposomes.

Claim 98. (New): The method of claim 97, wherein the adjuvant is Salmonella minnesota cells, bacille Calmette-Guerin, or QS21.

Claim 99. (New): The method of claim 91, wherein the antibodies induced are those that bind to antigens selected from the group consisting of (2,6)-sialyl T, Le^a, Le^b, Le^x, Le^y, GM1, SSEA-3, and Globo-H hexasaccharide.

Claim 100. (New): The method of claim 91, wherein the subject is in clinical remission or, where the subject has been treated by surgery, has limited unresected disease.